Phaseline

Companies › K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Azenosertib
Serine/threonine-protein kinase WEE1 inhibitor
WEE1Phase 3Ovarian Cancer; High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Solid Tumor; Uterine Serous Carcinoma …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05128825AzenosertibPhase 2High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerOncologyDec 2026
NCT06369155AzenosertibPhase 2Uterine Serous CarcinomaOncologyJan 2027
NCT06364410AzenosertibPhase 1Clinical Stage III Gastric Cancer AJCC v8OncologyJul 2027
NCT07546500AzenosertibPhase 3Ovarian CancerOncologyMay 2028
NCT04516447AzenosertibPhase 1Solid TumorOncologyJun 2028

Targets

WEE1 (1)

Companies with the same targets

AstraZeneca Aprea Therapeutics

Companies built like this

Maia Biotechnology FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio pharmaand

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.